Related Experiment Videos
Erythema dyschromicum perstans: response to dapsone therapy
Sevgi Bahadir1, Umit Cobanoglu, Gülseren Cimsit
1Department of Dermatology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey. umitco10@hotmail.com
International Journal of Dermatology
|March 11, 2004
Summary
Erythema dyschromicum perstans (EDP) is a rare skin pigmentation disorder. This case study shows dapsone effectively treated EDP, offering a potential therapeutic option.
Area of Science:
- Dermatology
- Rare skin disorders
Background:
- Erythema dyschromicum perstans (EDP) is a rare, progressive, ash-gray macular skin pigmentation disorder.
- Most reported cases are from Latin American and Indian populations, with rare occurrences in Turkey.
- Currently, no definitive treatment exists for EDP, and various therapies have proven ineffective.
Observation:
- A case of Erythema dyschromicum perstans was observed.
- The patient's condition was monitored for response to treatment.
- Previous treatments had shown no benefit.
Findings:
- The patient with Erythema dyschromicum perstans showed a remarkable response to dapsone therapy.
- Dapsone emerged as a potential effective treatment for this rare skin condition.
Implications:
- This finding suggests dapsone as a promising therapeutic agent for Erythema dyschromicum perstans.
- Further research into dapsone's efficacy for EDP is warranted.
- This could offer new hope for patients with this rare and persistent skin disorder.